Ernestina Lopez, RN-73580 Registered Nurse - School Medicare: Not Enrolled in Medicare Practice Location: 520 N Main St, Belen, NM 87002 Phone: 505-966-2207 |
Jacque Schneider, RN Registered Nurse - School Medicare: Not Enrolled in Medicare Practice Location: 19670 Hwy 314, Belen, NM 87002 Phone: 505-966-1800 |
Kelly Lopez, FPN Registered Nurse Medicare: Medicare Enrolled Practice Location: 320 N Main St, Belen, NM 87002 Phone: 505-361-1167 |
Ms. Julie Marie Brinkley, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 520 N Main St, Belen, NM 87002 Phone: 505-966-1612 Fax: 505-966-1265 |
Joseph Ryan Garcia, BSN RN Registered Nurse - School Medicare: Not Enrolled in Medicare Practice Location: 520 N Main St, Belen, NM 87002 Phone: 505-966-1270 Fax: 505-966-1265 |
Helen June Walton, Registered Nurse - School Medicare: Not Enrolled in Medicare Practice Location: 520 N Main St, Belen, NM 87002 Phone: 505-966-1271 Fax: 505-966-1265 |
News Archive
To be more transparent and to promote communication with patients after medical injuries, many hospitals have implemented a new approach called the communication-and-resolution program.
BAC BV, the leading provider of antibody-based affinity purification technology, has extended its collaboration with GE Healthcare with the addition of a new bioprocess affinity chromatography ligand to GE Healthcare's range of custom designed media. The latest addition to the range is an affinity resin for the purification of alpha-1 antitrypsin (AAT) from blood plasma, recombinant cell culture or transgenic sources. The new resin has been developed as part of GE Healthcare's Custom Designed Media (CDM) programme and provides a new solution for AAT purification in the biopharmaceutical industry.
onFocus Healthcare, Inc. today announced that it is the exclusive enterprise performance management solution to the Georgia Hospital Association (GHA) and its more than 200 hospitals. This partnership allows onFocus to extend its web-based software, onFocus|epmā¢, and performance optimization service programs through increased collaboration with GHA member hospitals and management teams.
Antisense Therapeutics Limited is pleased to announce that the Company has now completed repeat-dosing toxicology studies for ATL1103 in two species - mouse and non-human primate. Draft study reports from the study contractors in the United States have been received, and the toxicology outcomes from these studies support ANP's plans for the continued development of ATL1103.
Neovasc Inc., today announced financial results for the three and nine months ended September 30, 2009.
› Verified 8 days ago